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Abstract: The potential of nitric oxide (NO) as a rapid assay biomarker, one that could provide a quantum leap in acute
care, remains largely untapped. NO plays a crucial role as bronchodilator, vasodilator and inflammatory mediator. The
main objective of this review is to demonstrate how NO is a molecule of heavy interest in various acute disease states
along the emergency department and critical care spectrum: respiratory infections, central nervous system infections,
asthma, acute kidney injury, sepsis, septic shock, and myocardial ischemia, to name just a few. We discuss how NO and
its oxidative metabolites, nitrite and nitrate, are readily detectable in several body compartments and fluids, and as such
they are associated with many of the pathophysiological processes mentioned above. With methods such as high
performance liquid chromatography and chemiluminescence these entities are relatively easy and inexpensive to analyze.
Emphasis is placed on diagnostic rapidity, as this relates directly to quality of care in acute care situations. Further, a
rationale is provided for more bench, translational and clinical research in the field of NO biomarkers for such settings.
Developing standard protocols for the aforementioned disease states, centered on concentrations of NO and its
metabolites, can prove to revolutionize diagnostics and prognostication along a spectrum of clinical care. We present a
strong case for developing these biomarkers more as point-of-care assays with potential of color gradient test strips for
rapid screening of disease entities in acute care and beyond. This will be relevant to global health.

Keywords: Acute kidney injury, Acute myocardial ischemia, Acute respiratory illness, Asthma, Critical care, Emergency
department, Nitrate, Nitrite, Nitric Oxide, Sepsis, Shock.
INTRODUCTION
The emergency department (ED), closely linked to the
critical care setting, is widely used as first and last resort for
acute as well as chronic disease management. In fact, with
the advent of the economic recession in the U.S. and
concomitant loss of health insurance in families, usage of the
ED has increased tremendously [1, 2]. The ED and critical
care settings provide a unique clinical venue to develop, test
and implement novel biomarkers that can be cost-effective
and rapid in their ability to manage acute as well as chronic
disease processes with acute exacerbations. Much of the
current laboratory testing is cost and time inefficient and
presents detectable amounts of the biomarker only in the
later periods of the pathological cycle. For example, the most
prevalent traditional biomarker of renal dysfunction and the
gold-standard, serum creatinine, can take up to 72 hours to
rise in early acute renal failure (acute kidney injury);
baseline levels may be unavailable, thus it renders itself as a
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biomarker with limited utility in the acute setting [3, 4].
There is an unmet need for viable and rapid biomarkers for
various acute disease states, such as bronchiolitis, asthma,
influenza-like illness (with increased numbers during
pandemics), sepsis, shock, cardiovascular-related acute
ischemia / injury in the coronary and cerebral vasculature, to
name a few. Thus, these novel biomarkers can potentially
enhance disease management in a variety of clinical settings.
Nitric oxide (NO) and its metabolites, as potential
signaling molecules, are implicated in a wide variety of
physiological and pathological states. This review will cover
some of the more recent progress made in establishing the
utility, and limitations, of NO and its metabolites, nitrite and
nitrate, in a few acute disease states. The utility of these will
be extrapolated to disease processes beyond the ED, i.e., to
the critical care setting, along a continuum of care.
NITRIC OXIDE AND ITS METABOLITES: PHYSIOLOGICAL AND BIOCHEMICAL ASPECTS
NO as a highly reactive gaseous signaling molecule and
free radical is implicated in a variety of physiological and
biochemical processes (Fig. 1). Although it has been
associated with virtually every organ system in the body, it’s
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most important roles are 3 fold: regulation of blood flow in
the vascular endothelium (vascular homeostasis), neurotransmission and host defense mechanisms [5].

cardiovascular system, neuronal or nNOS, primarily
operational in producing NO as a neurotransmitter, and
inducible or iNOS, produced by a variety of cells
(endothelial and otherwise) for a variety of reasons,
including an immune-mediated or inflammatory response
[6]. Both the calcium dependent NOSs (eNOS and nNOS),
have transient activities and thus exhibit relatively low
concentrations, usually ranging in the nM range, while the

The predecessor to part of NO produced in the body is
the semi-essential amino acid L-arginine (Fig. 2). NO
production is catalyzed by 3 isoforms of NO synthase
(NOS): endothelial or eNOS by vascular endothelium in the
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Fig. (1). Nitric oxide (NO): Diversity in action.
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cytokine activated, calcium independent, iNOS is long
lasting, generating higher concentrations of NO, usually in
the µM range [6]. As a vascular effector, NO rapidly diffuses
from its site of generation in endothelial cells into adjacent
smooth muscle cells, where it activates soluble guanylate
cyclase (Fig. 2). The latter enzyme converts GTP to cGMP,
the second messenger that affects vascular smooth muscle
relaxation [7].
Once produced and active, NO can exist as the nitrosium
cation (NO+), the nitroxyl anion (NO-), and a NO free
radical (all with half lives < 20 s in circulation); all of these
forms then undergo a sequential oxidation or nitrosation of
water to form the more stable NO metabolites, nitrite
[t1/2=110 s in blood] and nitrate [t1/2=5-8 h in blood] [8] (Fig.
2). Fig. (2) also shows that nitrate and nitrite (collectively
referred to as NOx) can be recycled to produce NO (via
reduction) in various ways, one of which is the
enterosalivary circulation of endogenous nitrate, an essential
pathway in maintenance of NO homeostasis [8-11]. NOx in
blood as an index of eNOS activity has been widely used as
routine indirect measure of NO levels [12-15]. Recent
studies have indicated that nitrite is an important signaling
molecule in its own right [16, 17]. Since it can be reduced
back to NO given appropriate circumstances, this has led to
intense interest in this relatively simple molecule [18]. A
significant contribution of circulating levels of NOx is from
dietary intake of those moieties, and these can vary
tremendously from diet to diet [8]. During fasting conditions
with low dietary intake of NOx, enzymatic formation of NO
via NOS accounts for the majority of circulating NOx.
Nitrate and nitrite have been shown to be biomarkers for
cardiovascular and other diseases from both diagnostic and
therapeutic aspects [6, 8]. In addition to blood, urinary levels
of NOx provide a means to assess systemic production of
NO in vivo, however, with the caveat that urinary (or
plasma) levels are truly reflective of endogenous production
of NO, dietary ingestion of NOx, as well as from bacterial
activity in the gut [6, 8].
The interaction of NO and NOx with other moieties such
as superoxide (to form peroxynitrite), thiols (to form Snitrosothiols), secondary amines (to form N-nitrosoamines),
and metals (to form nitrosyl-heme) is also important
physiologically. As a free radical NO is bactericidal at
baseline, however, it has the additional property of
scavenging superoxide and by doing so protects against
injury [6]. The double edged nature of this reaction though is
evidenced by the resultant peroxynitrite, a potent cytotoxic
agent, implicated in disease processes, and an area of intense
research effort [19].
NO AND ITS METABOLITES IN ACUTE DISEASE
PROCESSES
NO and its Metabolites as Markers of Ongoing Infection
and Inflammation
In addition to the various physiological and biochemical
properties and functions described above, NO can also be a
biomarker for many inflammatory disease states, either local
to the tissue where generated or systemically. The effects of
NO as an inflammatory mediator have been studied in detail
for a length of time. NOS and NO induction have been
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shown to be innate immune effectors of infectious/inflammatory pathways [20]. The precise effect that NO has on
these disease states and inflammatory mediation is still under
debate. A recent study showing the temporal effects of NO
metabolites in a rodent model of systemic inflammation and
sepsis revealed tissue specific and time specific changes in
NO metabolites [21]. This highlights ‘the NO paradox’: is
NO a helpful mediator in inflammatory disease, or does it
function as a cytotoxic effector of non-specific immune
response? In a ‘too much of a good thing’ scenario, during
the immune response, moderate levels of NO prove
beneficial to the organism, while excess levels lead to too
much potency and thus damage.
NO and its Metabolites in Acute Respiratory Infections
Respiratory syncytial virus (RSV) and influenza can
cause major respiratory infections. RSV is the most common
cause of lower respiratory tract infections in children,
including bronchiolitis and pneumonia [22, 23]. There is a
broad spectrum of disease severity for bronchiolitis, the
leading cause of hospitalization for infants in the U.S. with
associated hospitalization costs in excess of $500 million per
year, as well as responsible for frequent ED visits [24, 25].
Pandemics like the 2009 novel swine-origin influenza A
(H1N1) virus (nH1N1) pose significant challenges: increased
transmission relative to seasonal influenza, severe disease in
patients with medical co-morbidities, and difficulty in
predicting which patients with viral respiratory symptoms
are at risk for influenza complications [26]. In the evaluation
of acutely ill patients with respiratory infections, risk
stratification may be achieved by utilizing biomarkers,
augmenting clinical decision-making, thus improving
outcomes. This is particularly relevant to the acute care
setting.
During influenza virus infection, epithelial cells,
macrophages, lymphocytes and other cells release a complex
series of cytokines and chemokines in an attempt to
overcome viral replication and disease progression [27-29].
NO, a key mediator of airway inflammation is also released.
It is unclear if increased NO activity is a marker of clinical
disease, of the innate antiviral response, or associated
significantly with a unique respiratory virus infection [30].
In the murine model of RSV for instance, NO production in
the lungs appears to be associated with viral clearance and
lung disease [31]. iNOS activity and production of NO were
associated with enhanced clearance of RSV, yet they were
also associated with airway inflammatory changes and
airway dysfunction [31]. In murine studies of experimental
influenza
A-triggered
pneumonia,
excessive
NO
biosynthesis, as measured by its metabolites nitrate and
nitrite, was demonstrated in the lungs [32, 33]. This
suggested that the metabolites may be markers of influenzamediated disease in the respiratory tract.
In humans, NO is produced in the upper and lower
respiratory tract. It can be detected in exhaled air of healthy
individuals and at increased levels in subjects with
pulmonary disease, including asthma (see below),
bronchiectasis and upper respiratory infections [34-38]. In
aqueous solutions, NO is rapidly converted to distinct oxides
of nitrogen, which may thus be potential biomarkers of
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disease severity in acutely ill patients presenting with
influenza-like-illness (ILI) [35, 39]. During the 2009 nH1N1
pandemic, we collected nasal wash specimens from children
with acute ILI, and then measured NOx concentration in the
nasal secretions by HPLC. Overall, our data suggested that
concentration of NO-derived nitrate in nasal secretions in
children may be related to type of viral pathogen causative
for acute ILI: RSV subtype B-associated ILI had higher
nasal wash nitrate compared to all other viruses combined
(P=0.002) [40]. Ongoing studies will determine the
predictive potential of this putative biomarker for important
disease outcomes in sicker patients requiring critical care.
Exhaled NO has been studied as a putative biomarker for
respiratory infections caused by influenza, rhinovirus and
other viral pathogens, but the data have been equivocal [41,
42]. The conflicting data above may simply reflect technical
issues in measuring exhaled NO. This methodology is
cumbersome to achieve in the pediatric population, either inpatient or ED. The newer NIOX-MINO hand-held NO
detector has proven to be as reliable as the older, stationary
chemiluminescence analyzer, the Ecomedics (ECO) [43]. Its
portability may make it easier to handle in acute care settings
of the ED or critical care. Focusing on stable NO metabolites
in nasal secretions from patients with acute ILI may still be
the better approach because of ready accessibility. Future
studies are needed that can establish correlations between
nasal secretion NOx and exhaled NO for acute ILI either in
the ED or critical care settings.
NO and its Metabolites in Acute Central Nervous System
(CNS) Infections
Meningitis can be a severe infection of the CNS.
Bacterial meningitis, in particular, remains an important
public health problem worldwide, with several studies
confirming the devastating neurological sequelae that may
result from it [44]. Cases of varying severity are likely to
pass through the ED; and the more severe ones then sent to
critical care. Early cerebrospinal fluid (CSF)-based
biomarkers are needed that may be able to predict severity,
so that potentially sicker patients can then get critical care
support. NO and its metabolites in the CSF may represent
such a biomarker. Studies have shown that patients admitted
to the hospital with bacterial meningitis and influenzaassociated encephalopathy had higher levels of CSF NOx as
compared to controls [45]. In another study, patients with
RSV infection and symptoms of encephalitis, encephalopathy or seizures were found to have a higher concentration
of CSF NOx compared with those with influenza positive
encephalopathy or those without meningitis [46]. Neither
were the studies set up in the ED nor did they analyze CSF
NOx in meningitis from different pathogens in the same
setting. Using a rapid HPLC-based assay for detection of
these metabolites in CSF in the acute setting may add to the
current armamentarium for helping in early diagnosis of
different forms of meningitis and may be predictive of
disease severity. Detecting CSF NOx in a rapid assay may be
particularly helpful in cases that are difficult to interpret,
such as in cases of CSF pleocytosis. The added information
may help guide management, ultimately resulting in better
disease outcomes.
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NO in Acute Asthma Exacerbations
Asthma is a major public health issue [47]. Acute asthma
exacerbations are common causes for pediatric and adult ED
visits with significant morbidity and mortality associated
with them [48]. Prompt diagnosis and treatment in the ED
and beyond are needed. There are no definitive diagnostic
and predictive tests for asthma, specifically in the acute
setting. NO is thought to play an important role in the
pathogenesis of asthma by modifying airway hyperreponsiveness and inflammation. Studies in asthmatic
children and adults have shown that fractional excretion of
nitric oxide (feNO) reflects the degree of airway
inflammation, with higher levels correlating with severity of
disease, likely secondary to inflammation. As such, it can be
a non-invasive biomarker for severity of the disease process
and response to treatment [49-51]. In several studies the
adequacy of anti-inflammatory treatment for chronic asthma
has been demonstrated by lowered concentration of feNO
[52-55], indicating the potential of NO as a management tool
for asthma. Based on this, Kwok et al. performed a crosssectional study in children 2-18 years of age presenting to an
urban ED with an acute asthma exacerbation [56]. Using a
tidal breathing method and a chemiluminescence-based NO
analyzer, they showed that only 68% of the subjects could
provide adequate breaths for feNO measurements [56].
Furthermore they showed that this method had limited utility
in the acute management of childhood asthma. A more
definitive answer for the utility of feNO in the acute setting
may be obtained in a study that follows the patients over a
longer duration than the typical 2-4 hour period covered by
Kwok et al. [56]. Although it may have been harder for
children to manage the respiratory maneuvers for the feNO
determination, it may be a more reliable tool for the adult
asthmatic population in acute care settings. Finally, an easier
to use device may be the answer. More recently, the portable
NIOX-MINO, mentioned above, has shown a high
correlation (r = 0.97, P < 0.001) with the more conventional
chemiluminescence device (NIOX) [57]. More encouraging
was that in the 55 children enrolled (4-9 years of age), up to
73% successfully provided feNO measurements, and thus
this may be a better tool for screening as well as
management of acute asthma in the pediatric and adult
population [57].
Since NO is a ubiquitous signaling molecule, perturbations in the NO pathway in the asthmatic airway over time
may be reflected in changes in levels of NO metabolites
measured elsewhere, such as plasma and urine. Determining
ratios between the levels of NO and its metabolites by
sampling different compartments may reveal a time course
reflecting evolution of the disease. Thus we may be able to
monitor NO from different compartments in different
settings (first in the ED and then during critical care) and at
different times indicating its biomarker potential for asthma
severity and management. Having better tools to diagnose,
predict and manage an acute asthma exacerbation would help
reduce the burden of this illness, particularly in the pediatric
population that is disproportionately affected by this
problem.
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NO and its Metabolites in Acute Kidney Injury
Acute kidney injury (AKI) is a common complication
among ambulatory and hospitalized patients, and can cause
significant morbidity and mortality, specifically in patients in
critical care medicine [58-61]. Patients, including pediatric
ones, who are or will get critically ill from AKI are likely to
pass through the ED [3, 4]. As alluded to in the introduction
to this review, the conventional biomarker for AKI, namely
serum creatinine, can take up to 3 days for an elevation or
change from baseline, indicative of worsening renal function
[60, 62, 63]. Thus, additional early biomarkers are needed
that can be diagnostic and prognostic of AKI in the ED and
critical care settings, at a time when baseline serum
creatinine is either unavailable or uninformative. NO has
been shown to have several functions in the kidney,
depending on its concentration, site of release, and duration
of action [64]. Endothelial injury and the subsequent
microcirculatory dysfunction is likely a primary event in
renal hypoxia with disturbances in NO-related pathways
playing key roles [65]. In an adult post-ischemic model of
AKI urinary concentration of NO (as measured by its
metabolites nitrate and nitrite) were markedly lower
suggesting that this was a reflection of potential endothelial
damage in the kidney [66]. Thus, we conducted a study to
test the hypothesis that urinary concentration of nitrate and
nitrite would be decreased in early AKI in children

presenting to the ED [4]. We showed that in 252 patients, 019 years of age presenting to the pediatric ED, lower
concentration of urinary nitrate, but not nitrite, was
significantly associated with AKI (Fig. 3), thus indicating the
potential for this as a novel urinary biomarker for AKI in the
ED [4]. More encouraging was the potential for this urinary
biomarker in the face of a normal serum creatinine in almost
half of those with AKI [4]. Future studies are needed to
evaluate fully the ability of urinary nitrate to predict
important in-patient clinical outcomes, such as critical care
needs, dialysis, and ultimately mortality. As mentioned
above, urinary NO metabolites are a reflection of both
dietary intake of NOx as well as endogenous generation of
NO, thus additional studies are needed to determine whether
diminished level of urinary nitrate in AKI is truly indicative
of renal endothelial dysfunction.
NO and its Metabolites in Sepsis and Septic Shock
Sepsis is defined as the systemic response to infection,
and about half of those patients progress to septic shock
characterized by refractory hypotension and multiple organ
failure [6]. Severe sepsis and septic shock are associated
with significant mortality, as high as 28% [67].
Hemodynamically, both macro- as well as microcirculatory
failure is the hallmark of severe sepsis and septic shock [67].

Median nitrate/Cr [µg/mg Cr]

*

No AKI and at
risk for AKI
(Combined)

With AKI

Fig. (3). Urinary nitrate distinguishes patients with acute kidney injury (AKI) from those either at risk or without AKI. Data based on ref. [4],
shows median urinary nitrate normalized to urinary creatinine in patients presenting to TCH [N=252]. Bar on left represents combined no
AKI and at risk for AKI, whereas the one on the right represents those with AKI. Data are shown as box plots with the heavy line in the box
representing the median (50th percentile) and the ends of the box representing 25th and 75th percentiles, respectively. Groups were compared
using the non-parametric Mann Whitney U test (*P=0.02). Cr, creatinine. TCH, Texas Children’s Hospital.
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The central role of NO in maintaining microcirculation is
highlighted in sepsis and septic shock, states in which the
microcirculation has sustained an insult. Several studies have
implicated the overproduction of NO as the cause for the
decompensated state [6]. Sepsis, septic shock or systemic
inflammatory response syndrome in intensive care settings is
associated with increased plasma nitrate and nitrite [68-70].
Measuring both plasma and urinary NOx has revealed
elevations in patients with sepsis and septic shock [6]. Innate
immune pathway activation in response to infection and
inflammation, particularly in sepsis and shock, is associated
with increased activity of iNOS, and thus more NO being
released [20, 71]. However, studies in experimental animals
reveal that iNOS upregulation and production of NO may
have a feedback inhibition on constitutive NO production in
other tissues [21, 72]. Urinary NOx reflects both the
production and utilization of NO [73, 74]. Nitrate is the main
urinary NO metabolite, whereas nitrite is low to undetectable
in urine [75]. Sepsis and shock can expose the kidney to
ischemic injury and this can be reflected in low levels of
uNOx excretion likely due to low endogenous NO
generation [4, 66]. Conversely, since the majority (96%) of
filtered nitrate and nitrite is reabsorbed by the renal tubules,
high levels in urine secondary to reduced renal reabsorption
may reflect acute renal failure concomitant with sepsis/septic
shock [4, 76].
Although NO directly as well as by conversion to
peroxynitrite can be bactericidal, excessive levels are
counterproductive as evidenced by the refractory
vasodilation, hypotension and decreased tissue perfusion [6].
Irrespective of mechanism and level of metabolite, NO as a
downstream effector of innate immune activation lends itself
as a potential biomarker for sepsis and septic shock. This
may be particularly useful in the acute setting as the
concentration of NOx in plasma or urine may predict
important in-patient clinical outcomes, such as need for
hospitalization, level of support (intensive care versus
regular floor), and mortality.
NO and its Metabolites in Acute Myocardial Infarction:
Going Beyond Diagnostic Biomarkers to Therapeutic
Intervention
As stated at the outset a continuous endogenous supply of
NO is crucial for the physiological integrity of the
cardiovascular system. In fact, an imbalance in the
production or bioavailability of NO is unequivocally linked
to cardiovascular pathology. With more recent advances in
establishing the nitrate-nitrite-NO pathway, the reverse
pathway that enables more NO to be generated when
endogenous NOS pathways are dysfunctional, harnessing it
therapeutically in prevention and treatment of cardiovascular
disease becomes self-evident [77-79]. Ischemic heart disease
is a major player in the acute care setting. In this disease
process where regional hypoxia and ischemia prevail, it may
be of great benefit to replenish the stores of NOx either
pharmacologically or through diet [77, 78]. In the past,
dietary NOx had been granted pariah status because of
nebulous links to disease [78]. With greater evidence
suggesting benefits of the oxidative NO metabolites in
ischemia/reperfusion injury, a real paradigm shift is needed
in the scientific community from the perspective of the
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relatively simple inorganic anions nitrate and nitrite. Nitrite,
in fact, may be the endocrine mediator of NO-based
signaling [80]. Bolusing nitrite intravenously prior to
instigating a cardiovascular insult has been shown to
significantly reduce the injury not only from myocardial
infarction, but also ischemic liver and kidney injury and
stroke in multiple animal models [81-84]. These pre-clinical
or benchwork-based experiments have prompted several
human clinical trials on NOx for cardiovascular
complications like acute ischemia. In a very promising study
nitrite therapy was shown to improve cardiac and
neurological function and overall survival post cardiac arrest
[85]. Initiating NOx-based clinical efficacy trials in the acute
setting are justified since that is where cardiovascular
complications like acute MI and cardiac arrest are first
encountered by the medical team. These interventions will
likely improve acute care management from the
cardiovascular morbidity and mortality perspective.
CONCLUSIONS AND FUTURE
ACUTE CARE AND BEYOND

DIRECTIONS:

This review has focused on the role of NO and its
metabolites in a few disease processes commonly
encountered in the acute care setting (sumarized in Fig. 2).
We have argued that NO and its metabolites nitrate and
nitrite can be potential biomarkers that need to be developed
further from a diagnostic and prognostic perspective and that
is likely to improve management in the acute care setting.
Measured exhaled NO (feNO) concentration is immediately
available and may be a reliable tool for assessment of airway
inflammation in an acute asthma exacerbation. Concentration
of NOx in multiple biological samples (plasma, urine, nasal
secretion, CSF) measured via HPLC can also be reliably
obtained in a rapid manner since the HPLC run per sample
takes an average of 8 minutes [8]. Samples can be batched
and run on the HPLC. Hence, both NO and NOx have the
potential of being rapidly determined biomarkers for
multiple disease processes encountered in the acute care
setting (summarized in Fig. 2).
There are limitations to using NO and it’s metabolites as
biomarkers. Although NOx can give a fairly reliable idea of
systemic NO bioavailability, its concentration in urine and
plasma being heavily dependent on renal activity, it cannot
be an entirely accurate measure of NOS functionality.
Additionally, the presence of nitrite and nitrate in everyday
diet adds another restriction towards using NOx in plasma
and urine as absolutely indicative of disease process [8].
Single feNO or NOx determinations simply may not be
enough. Thus, sequential measurements of the biomarkers
may be needed to get a better handle on the evolution of the
disease process, initially as the patient presents in the acute
phase and then during the course of critical care. Further,
sampling from multiple compartments may be more
informative of the disease process. For instance, for AKI,
plasma and urinary NOx measurements simultaneously
would enable us to determine the fractional excretion of
urinary NO metabolites, potentially a more informative
parameter for the disease entity than urinary NOx alone.
Given the non-specific nature of NO and its metabolites,
they will be unlikely to entirely replace pre-existing tests.
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Hence, this type of analysis should be in addition to the
standard diagnostics and biomarkers. Having a more
comprehensive picture will only improve diagnosis,
prognosis and effectiveness of treatment and reveal how NO
is or may be playing a role in the acute disease process. NObased analyses might not be able to differentiate between
primary pulmonary versus cardiac disease. However, in the
setting of a relevant clinical presentation and work up,
analyzing NO and metabolites might be a valuable
assessment for a NO component, and as such, an adjunct.
General state of health and co-morbid disease states
might influence results, and hence have significant
limitations on the use of NO or NO metabolites as
biomarkers. Dietary NOx, as alluded to above, is a
potentially significant limitation due to the fact that in the
ED and critical care settings we cannot always predict or
select patients based on fasted states or dietary patterns.
There is obvious value in obtaining a non-invasive
specimen for determining levels of biomarkers for disease
states. This will require the development, validation and then
clinical usage of relatively simple, rapid and cost-effective
techniques that may sample multiple body fluids collected
non-invasively, such as nasal washes, saliva and urine [86].
Future studies will improve our understanding of NO
pathophysiology and thus enable us to rationally devise
pharmacological treatment for manipulating NO in acute
disease states. While many of these therapeutic approaches
remain speculative, better understanding of the underlying
mechanisms that regulate NO function will ultimately
improve our ability to implement such therapies. Adaptation
to and validation of a point-of-care test with the assistance of
an industry partner will enable inexpensive screening
capacity on a dipstick, point-of-care type of a platform, to
aid treatment decisions [87]. This has obvious global health
implications that go far beyond any specific clinical setting
[87].
Overall, what is most importantly highlighted, for acute
care and non-acute care physicians alike, is the ongoing
research need to determine the physiological roles of NOx,
and if it can be used unequivocally both as diagnostic
biomarker of disease and for treatment regimens, in a variety
of clinical settings.
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